Upregulation of long noncoding RNA XIST is associated with poor prognosis in human cancers
Journal of Cellular Physiology
Published online on October 20, 2018
Abstract
---
- "\nAbstract\nGrowing evidence from recent studies has shown that the X‐inactive
specific transcript (XIST), a well‐known long noncoding RNA involved in early embryonic
development, is aberrantly regulated in various human cancers. However, the prognostic
value of XIST in cancers remains uncharacterized. In this study, we searched PubMed,
Web of Science, and Embase to collect all relevant studies, and a meta‐analysis
was performed to explore the association of XIST expression with overall survival
(OS) and clinicopathological parameters. We demonstrated that high XIST expression
was associated with poor OS (hazard ratio = 1.76; 95% confidence intervals [CI],
1.56–1.98; p < 0.001). In addition, increased XIST expression was found to be associated
with lymph node metastasis (odds ratio [OR] = 2.06; 95% CI, 1.46–1.90; \np < 0.001),
distant metastasis (OR = 2.93; 95% CI, 2.00–4.28; \np < 0.001), tumor size (OR = 2.66;
95% CI, 1.86–3.81; \np < 0.001), poor differentiation (OR = 1.45; 95% CI, 1.00–2.10;
\np = 0.049), and advanced tumor stage (OR = 3.35; 95% CI, 2.25–5.00; \np < 0.001),
but not with age (OR = 0.82; 95% CI, 0.59–1.15; \np = 0.251) or gender (OR = 0.92;
95% CI, 0.70–1.19; \np = 0.512). Our meta‐analysis showed that XIST may be a useful
common biomarker for predicting prognosis in patients with cancer."
- Journal of Cellular Physiology, EarlyView.